Literature DB >> 24616415

Role of RET genetic variants in MEN2-associated pheochromocytoma.

Débora Rodrigues Siqueira1, Lucieli Ceolin1, Carla Vaz Ferreira1, Mírian Romitti1, Silvana Cavalcante Maia1, Léa Maria Zanini Maciel1, Ana Luiza Maia2.   

Abstract

BACKGROUND: RET polymorphisms have been involved in the clinical presentation and prognosis of multiple endocrine neoplasia type 2 (MEN2)-associated medullary thyroid carcinoma.
OBJECTIVE: To investigate the effect of RET variants on the penetrance of pheochromocytoma (PHEO) in MEN2 patients.
METHODS: The RET variants L769L, S836S, and G691S/S904S were evaluated in a cohort of 153 MEN2 patients attending a tertiary teaching hospital. A comparison of RET variant frequencies between patients with and without PHEO was performed. Kaplan-Meier curves and Cox regression analysis were used to estimate the effect of RET variants on the age-dependent penetrance.
RESULTS: A total of 48 (31.4%) patients presented with MEN2-associated PHEOs. The mean age at diagnosis was 35.5±13.4 years, 60.4% of patients were women, and 92.8% had RET mutations at codon 634. The frequencies of RET polymorphisms were as follows: 20.1% L769L, 4.75% S836S, and 17.3% S904S/G691S. We did not observe any association between the frequencies of L769L, S836S, or S904S/G691S variants and PHEO development (all P>0.05). However, individuals carrying two RET polymorphic alleles had an increased estimated risk of PHEO (2.63; 95% CI, 1.4-5.0; P=0.004) and were younger at diagnosis when compared with those with one or no polymorphism (29.6±6.3 and 39.3±14.4 years respectively; P=0.006). Accordingly, additional analysis using Cox proportional hazard models demonstrated that the presence of two RET variants was associated with an increased risk for early PHEO development (hazard ratio, 5.99 (95% CI, 2.24-16.03); P<0.001).
CONCLUSIONS: RET polymorphic alleles have an additive effect on the estimated risk of age-related PHEO penetrance in MEN2 patients.
© 2014 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24616415     DOI: 10.1530/EJE-14-0084

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

Review 1.  MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Authors:  Vincent Amodru; David Taieb; Carole Guerin; Pauline Romanet; Nunzia Paladino; Thierry Brue; Thomas Cuny; Anne Barlier; Frederic Sebag; Frederic Castinetti
Journal:  Endocrine       Date:  2020-05-10       Impact factor: 3.633

2.  Bilateral Pheochromocytomas in MEN2A Syndrome: A Two-Institution Experience.

Authors:  Brian Hung-Hin Lang; Hyeong Won Yu; Chung-Yau Lo; Kyu Eun Lee; Maria-Mercedes Garcia-Barcelo; Yu Cho Woo; Paul C H Lee; Kai Pun Wong; Paul K H Tam; Karen S L Lam
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

3.  RET c.1901G&gt;A and Novel SLC12A3 Mutations in Familial Pheochromocytomas.

Authors:  Lin Zhao; Kun-Qi Yang; Peng Fan; Ding-Xu Gong; Lin Zhang; Yi-Ting Lu; Xu Meng; Xian-Liang Zhou
Journal:  Genes (Basel)       Date:  2022-05-12       Impact factor: 4.141

4.  Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing.

Authors:  Zhen-Fang DU; Peng-Fei Li; Jian-Qiang Zhao; Zhi-Lie Cao; Feng Li; Ju-Ming Ma; Xiao-Ping Qi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

5.  Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A.

Authors:  Rowena Speak; Jackie Cook; Barney Harrison; John Newell-Price
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-11-25

6.  Atypical presentation of bladder pheochromocytoma.

Authors:  Chen-Yueh Wen; Chung-Tai Yu; Cheng-Hsing Hsieh
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Jan-Mar

7.  Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.

Authors:  Xiao-Ping Qi; Jian-Qiang Zhao; Xu-Dong Fang; Bi-Jun Lian; Feng Li; Hui-Hong Wang; Zhi-Lie Cao; Wei-Hui Zheng; Juan Cao; Yu Chen
Journal:  BMC Cancer       Date:  2021-04-07       Impact factor: 4.430

8.  Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma.

Authors:  Anna Skalniak; Małgorzata Trofimiuk-Müldner; Elwira Przybylik-Mazurek; Alicja Hubalewska-Dydejczyk
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

9.  Biochemistry may be misleading in metachronous MEN2A-associated phaeochromocytoma following unilateral total adrenalectomy.

Authors:  Anthony-Joe Nassour; Carolina Nylen; Mark Sywak; Roderick Clifton-Bligh
Journal:  BMJ Case Rep       Date:  2020-06-11

10.  Effect of 3'UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma.

Authors:  Lucieli Ceolin; Mirian Romitti; Débora Rodrigues Siqueira; Carla Vaz Ferreira; Jessica Oliboni Scapineli; Beatriz Assis-Brazil; Rodolfo Vieira Maximiano; Tauanne Dias Amarante; Miriam Celi de Souza Nunes; Gerald Weber; Ana Luiza Maia
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.